1. Thanongsaksrikul J, Chaicumpa W. Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins (Basel). 2011;3(5):469-88. [
Link] [
DOI:10.3390/toxins3050469]
2. Mousavi SJ, Rashidiani J, Farasat A, Ebrahimi F. Recombinant expression of light chain of botulinum neurotoxin type-A in E. coli and evalution of its enzymatic activity. Mol Biol Res Commun. 2014;3(1):58-60. [Persian] [
Link]
3. Leclair D, Farber JM, Pagotto F, Suppa S, Doidge B, Austin JW. Tracking sources of Clostridium botulinum type E contamination in seal meat. Int J Circumpolar Health. 2017;76(1):1380994. [
Link] [
DOI:10.1080/22423982.2017.1380994]
4. Kukreja R, Singh B. The botulinum toxin as a therapeutic agent: Molecular and pharmacological insights. Res Rep Biochem. 2015;5:173-83. [
Link]
5. Lakshminarasimhan D, Kumaran D, Agarwal R, Singh BR. Cloning, expression and purification of botulinum neurotoxin type A heavy chain-crystallographic evidence for a putative tetrameric pore. Botulinum J. 2012;2(2):135-49. [
Link] [
DOI:10.1504/TBJ.2012.050196]
6. Horowitz BZ. Type E botulism. Clin Toxicol (Phila). 2010;48(9):880-95. [
Link] [
DOI:10.3109/15563650.2010.526943]
7. Kiris E, Burnett JC, Kane CD, Bavari S. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem. 2014;14(18):2044-61. [
Link] [
DOI:10.2174/1568026614666141022093350]
8. Mousavi ML, Kouhsari SM, Nazarian Sh, Rasooli I, Amani J. Cloning, expression and purification of Clostridium botulinum neurotoxin type E binding domain. Iran J Biotechnol. 2004;2(3):183-8. [
Link]
9. Hamidi B, Ebrahimi F, Hajizadeh A, Hajizadeh A, Keshavarz Alikhani H. Fusion and cloning of the binding domains of botulinum neurotoxin type A and B in E. coli DH5α. Eur J Experimental Biol. 2012;2(4):1154-60. [
Link]
10. Derman Y, Selby K, Miethe S, Frenzel A, Liu Y, Rasetti-Escargueil C, et al. Neutralization of botulinum Neurotoxin Type E by a humanized antibody. Toxins (Basel). 2016;8(9):257. [
Link]
11. Agarwal R, Eswaramoorthy S, Kumaran D, Dunn JJ, Swaminathan S. Cloning, high level expression, purification, and crystallization of the full length Clostridium botulinum neurotoxin type E light chain. Protein Expr Purif. 2004;34(1):95-102. [
Link]
12. Agarwal R, Swaminathan S. SNAP-25 substrate peptide (residues 180–183) binds to but bypasses cleavage by catalytically active Clostridium botulinum Neurotoxin E-. J Biol Chem. 2008;283(38):25944-51. [
Link] [
DOI:10.1074/jbc.M803756200]
13. Sambrook J, MacCallum P, Russell D. Molecular cloning A laboratory Manual. 3rd Volume. New York: Cold Spring Harbor Laboratory Press; 2001. pp. 6-12. [
Link]
14. Ralph R. The nucleic acid protocols hand book. New York: Humana Press; 2000. [
Link]
15. Ebrahimi F, Rasaee MJ, Mousavi SL, Babaeipour V. Production and characterization of a recombinant chimeric antigen consisting botulinum neurotoxin serotypes A, B and E binding subdomains. J Toxicol Sci. 2010;35(1):9-19. [
Link] [
DOI:10.2131/jts.35.9]
16. Bollag DM, Rozycki MD, Edelstein SJ. Protein methods. New York: Wiley-Liss; 1991. [
Link]
17. Gouy M, Gautier C. Codon usage in bacteria: Correlation with gene expressivity. Nucleic Acids Res. 1982;10(22):7055-74. [
Link] [
DOI:10.1093/nar/10.22.7055]
18. Zdanovsky AG, Zdanovskaia MV. Simple and efficient method for heterologous expression of clostridial proteins. Appl Environ Microbiol. 2000;66(8):3166-73. [
Link] [
DOI:10.1128/AEM.66.8.3166-3173.2000]
19. Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol. 1999;291(5):1091-104. [
Link] [
DOI:10.1006/jmbi.1999.2945]